FOLFIRI；伊立替康,临床注释,变异和临床注释数据

FOLFIRI；伊立替康

临床注释ID

1451204660

药物名称(英)

FOLFIRI;irinotecan

变异单倍型

UGT1A1*1, UGT1A1*28

基因

UGT1A1

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

224.0

PMID计数

计数的证据

表现型

中性粒细胞减少症

表现型(英)

Neutropenia

最新日期

2021-04-01

URL

https://www.pharmgkb.org/clinicalAnnotation/1451204660

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
150	*28	The UGT1A128 allele has been assigned as a decreased function allele by CPIC. Patients carrying the UGT1A128 allele in combination with a normal function allele may have increased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased likelihood of neutropenia compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.
149	*1	The UGT1A11 allele has been assigned as a normal function allele by CPIC. Patients carrying the UGT1A11 allele in combination with another normal function allele may have decreased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.

临床证据

id	证据的ID	总结
14639	1451210000	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 1/1 + 1/28.
14638	1451209909	UGT1A1 1/28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 1/1.
14637	1451209900	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 1/1.
14636	1451209760	UGT1A1 1/28 is not associated with Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 1/1.
14635	1451209203	UGT1A1 1/28 + 28/28 are associated with increased severity of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1.
14634	1451209004	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1 + 1/28 + 1/37.
14633	1451208889	UGT1A1 1/28 + 28/28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1.
14632	1451208752	UGT1A1 1/28 + 28/28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1.
14631	1451208420	UGT1A1 28/28 is not associated with increased risk of Diarrhea or Neutropenia when treated with irinotecan in children with Neoplasms as compared to UGT1A1 1/1 + 1/28.
14630	1451207282	UGT1A1 1/28 + 28/28 are associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
14629	1451207040	UGT1A1 1/28 + 28/28 are associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
14628	1451206820	UGT1A1 1/28 + 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
14627	1451206444	UGT1A1 1/28 + 28/28 are not associated with Neutropenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
14626	1451206354	UGT1A1 1/28 + 28/28 are not associated with Anemia, mucositis, Nausea, Neutropenia or Thrombocytopenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
14625	1451205620	UGT1A1 28/28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 1/1.
14624	1451205440	UGT1A1 28/28 is associated with increased likelihood of Anemia, Leukopenia, Neutropenia or Thrombocytopenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 1/1.
14623	1451205360	UGT1A1 1/28 + 28/28 are not associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 1/1.
14622	1451205308	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1 + 1/28.
14621	1451204842	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1 + 1/28.
14620	1448519703	UGT1A1 28/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1/1 + 1/28.
14618	PA166104831	Annotation of FDA Label for irinotecan and UGT1A1
14513	1448427979	UGT1A1 28 is not associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1.
14512	1448422855	UGT1A1 1/28 + 6/28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 1/1.
14511	1448422676	UGT1A1 6 + 28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.
14510	1184483709	UGT1A1 6/6 + 28/28 + 6/28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/6 + 1/28 + 1/1.
14509	1184483429	UGT1A1 6 + 28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.
14508	1184483423	UGT1A1 *28 is not associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.
89	1451214800	UGT1A1 28/28 + 28/37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1/1 + 1/28.
88	1451214143	UGT1A1 1/28 + 28/28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 1/1.
87	1451214002	UGT1A1 28 is not associated with increased risk of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1.
86	1451213905	UGT1A1 1/28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 1/1.
85	1451213606	UGT1A1 1/28 is not associated with increased likelihood of Anemia, Leukopenia, Neutropenia, Thrombocytopenia or Vomiting when treated with irinotecan in people with Neoplasms as compared to UGT1A1 1/1.
84	1451213580	UGT1A1 *28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms.
83	1451213421	UGT1A1 28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 1.
82	1451212280	UGT1A1 1/28 + 28/28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
81	1451211900	UGT1A1 28 is not associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 1.
80	1451211808	UGT1A1 1/28 + 28/28 are associated with increased Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 1/1.
79	1451211761	UGT1A1 28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 1.
78	1451210158	UGT1A1 28/28 + 6/6 + 1/6 + 1/28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 1/1.
42	PA166104951	Annotation of DPWG Guideline for irinotecan and UGT1A1

临床病史

id	类型	评论
254	Update	Added DPWG guideline for irinotecan.
253	Update	CA score added as part of scoring system release. LOE assigned following curator review.
252	Update	Added FDA label and moved *6 VAs to a new CA
251	Update	Minor edits to phenotype descriptions
250	Update	Formatted text to new standard, added 6 and VAs for 6
249	Update	This annotation includes studies with irinotecan and irinotecan regimens such as FOLFIRI.
248	Update	Refined phenotype to just neutropenia.
247	Create	Created
246	Update	This replaces annotation 981750843 on retired rs number rs8175347

最新招商产品更多>>